Halozyme Therapeutics (MIL:1HALO) Beginning Cash Position: €271 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MIL:1HALO Halozyme Therapeutics Inc MIL:1HALO
72 GF Score
Price €87.66
GF Value €83.00
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Halozyme Therapeutics Beginning Cash Position?

Halozyme Therapeutics MIL:1HALO 72 Beginning Cash Position is €271 Mil as of Jun. 2026. GuruFocus rates MIL:1HALO with a GF Score™ of 72/100 and a GF Value™ of €83.00 (Fairly Valued). The stock has 4 warning signs investors should review.

Halozyme Therapeutics's Beginning Cash Position for the quarter that ended in Jun. 2026 was €271 Mil.

Halozyme Therapeutics's quarterly Beginning Cash Position declined from Dec. 2025 (€358 Mil) to Mar. 2026 (€118 Mil) but then increased from Mar. 2026 (€118 Mil) to Jun. 2026 (€271 Mil).

Halozyme Therapeutics's annual Beginning Cash Position declined from Dec. 2023 (€215 Mil) to Dec. 2024 (€113 Mil) and declined from Dec. 2024 (€113 Mil) to Dec. 2025 (€99 Mil).

Halozyme Therapeutics Beginning Cash Position Related Terms

Halozyme Therapeutics Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for Halozyme Therapeutics's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Halozyme Therapeutics Beginning Cash Position Chart

Halozyme Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beginning Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 131.16 112.54 215.22 113.04 98.94

Halozyme Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 152.88 52.71 358.39 118.01 270.82
MIL:1HALO
72GF Score
Halozyme Therapeutics Inc MIL:1HALO
Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Halozyme Therapeutics Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of €271 Mil mean?
Halozyme Therapeutics (MIL:1HALO) has a Beginning Cash Position of €271 Mil as of Jun. 2026. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Halozyme Therapeutics and its competitors.
Is Halozyme Therapeutics' Beginning Cash Position too high?
Halozyme Therapeutics' current Beginning Cash Position is €271 Mil. Overall, Halozyme Therapeutics has a GF Score™ of 72/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Halozyme Therapeutics' Beginning Cash Position compare to NUVL and KRYS?
Halozyme Therapeutics' Beginning Cash Position of €271 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Biotechnology company?
A good Beginning Cash Position depends on the Biotechnology industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Halozyme Therapeutics and its competitors. Halozyme Therapeutics's current Beginning Cash Position is €271 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Halozyme Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Halozyme Therapeutics (MIL:1HALO) is currently considered Fairly Valued. The stock's GF Value™ is €83.00, compared to a current price of €87.66 — trading 5.6% above its estimated fair value. The current Beginning Cash Position is €271 Mil. Halozyme Therapeutics' overall GF Score™ is 72/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For Halozyme Therapeutics (MIL:1HALO), the current Beginning Cash Position is €271 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Halozyme Therapeutics (MIL:1HALO) Overvalued in 2026?

Based on GuruFocus' analysis, Halozyme Therapeutics stock appears to be overvalued. The current stock price of €87.66 is trading 5.6% above its estimated GF Value™ of €83.00. GuruFocus considers Halozyme Therapeutics to be Fairly Valued.

Key valuation signals for MIL:1HALO:

  • Beginning Cash Position: €271 Mil
  • GF Value™: €83.00 vs. price of €87.66 (5.6% above fair value)
  • GF Score™: 72/100 with 4 warning signs

No single metric tells the full story. See the MIL:1HALO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Halozyme Therapeutics Business Description

Address 12390 El Camino Real, San Diego, CA, USA, 92130
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.
72GF Score

Get the complete analysis for MIL:1HALO

Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€87.66
Price
€83.00
GF Value